Medicines the European Medicines Agency has recommended for use in the European Union on this topic.
Each number has its full source under its own list below.
68 medicines (authorised now). Newest first. Each links to its EMA page.
Active substance: A/(H1N1)-like virus antigen;A/(H3N2)-like virus antigen;B (Victoria lineage)-like virus antigen
Active substance: single-stranded, 5’-capped messenger RNAs (mRNAs) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding seasonal infl…
Active substance: clesrovimab
Active substance: A/California/07/2009 (H1N1)pdm09-like strain (A/California/07/2009);A/Texas/50/2012 (H3N2)-like strain (A/Texas/50/2012);B/Brisbane/60/2008-like strain (B/Bris…
Active substance: single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding the N-terminal…
Active substance: recombinant pertussis toxin;filamentous haemagglutinin
Active substance: human normal immunoglobulin
Active substance: pneumococcal polysaccharide serotype 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B de-O-acetylated, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B conjuga…
Active substance: Chikungunya virus (CHIKV) virus-like particle (VLP) proteins (capsid protein (C) and envelope proteins E1 and E2) derived from CHIKV Senegal strain 37997 produ…
Active substance: COVID-19 sa-mRNA Vaccine
Active substance: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Tasmania/318/2025, CVR-351);A/Darwin/1415/2025 (H3N2)-like strain (A/Tasmania/787/2025, CVR-388);B/Pennsylvania/1…
Active substance: Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation
Active substance: Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated
Active substance: influenza virus (live attenuated);A/Missouri/11/2025 (H1N1)pdm09 - like strain (A/Switzerland/6849/2025, MEDI 400592);A/Darwin/1454/2025 (H3N2) - like strain (…
Active substance: Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen
Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.
Countries side by side on public measures for this topic.
Worldwide · 2024–2034
View report PharmaceuticalsWorldwide · 2024–2034
View report PharmaceuticalsWorldwide · 2024–2034
View report PharmaceuticalsWorldwide · 2024–2034
View report Public HealthWorldwide · 2024–2034
View report Public HealthWorldwide · 2024–2034
View reportAcuitas market sizes and forecasts are only in our full reports. How we use public data.